1例妊娠期艰难梭菌感染伴尿路感染患者的药学监护

doi:10.19803/j.1672-8629.20220036

摘要/Abstract

摘要： 目的分析1例妊娠期艰难梭菌感染（CDI）伴尿路感染患者的病例,探讨其抗感染方案的合理性,为该类患者的临床合理用药提供参考。方法临床药师全程参与1例妊娠期CDI伴尿路感染患者治疗的诊治过程,通过检索国内外相关文献,严格遵循循证医学证据并结合患者个体情况,协助医师制定抗感染治疗方案,采用口服甲硝唑治疗CDI,哌拉西林他唑巴坦治疗尿路感染。结果临床药师协助医师治愈了肠道CDI及泌尿道感染,保证了母胎安全。结论临床药师应遵循循证方法结合个体情况制定方案,针对并发感染用药应权衡利弊,在保证母胎安全的前提下解决感染问题,体现妇产科临床药师的职业价值。

关键词: 妊娠期, 艰难梭菌感染, 尿路感染, 抗感染治疗, 合理用药

Abstract: Objective To analyze one case of pregnancy with Clostridium difficile infection and urinary tract infection, explore the rationality of the anti-infection treatment and provide reference for clinical rational drug use. Methods A clinical pharmacist participated in the treatment of a pregnant patient with Clostridium difficile infection and urinary tract infection. By retrieving related literature, strictly following the evidence-based medical practice and taking the patient’s conditions into consideration, the clinical pharmacist assisted the doctor in formulating the anti-infection treatment plan. Oral metronidazole and venous piperacillin tazobactam were used to treat Clostridium difficile infection and urinary tract infection, respectively. Results The clinical pharmacist helped doctors cure the infections and ensured the safety of the mother and fetus. Conclusion Clinical pharmacists should follow evidence-based methods and formulate a plan in combination with individual conditions. For the medication of concurrent infections, they should weigh the advantages and disadvantages and cure infections as long as the safety of the mother and fetus can be ensured, which can manifest the value of clinical pharmacists in obstetrics and gynecology.

Key words: pregnant, Clostridium difficile infection, urinary tract infection, anti-infection treatment, rational drug use

中图分类号:

R978
R969.3

范秀丛, 董晓慧, 陈丹霞, 鲍思蔚, 马雅斌. 1例妊娠期艰难梭菌感染伴尿路感染患者的药学监护[J]. 中国药物警戒, 2023, 20(5): 579-582.

FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin. Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.

参考文献

[1] SURAWICZ CM, BRANDT LJ, BINION DG, et al.Guidelines for diagnosis,treatment,and prevention of Clostridium difficile infections[J]. Am J Gastroentero, 2013, 108(4): 478-498.
[2] WU Y, LU JX, YAN ZQ, et al.Interpretation of diagnostic group standard for clostridium difficile infection[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2021, 42(1): 64-67.
[3] COHEN SH, GERDING DN, JOHNSON S, et al.Clinical practice guidelines or Clostridium difficile infection in adults: 2010 update by the society for ealthcare epidemiology of America SHEA and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol, 2010, 31(5):431-455.
[4] ROUPHAEL NG, DONNELL JA, BHATNAGAR J, et al. Clostridium difficile-associated diarrhea: An emerging threat to pregnant women[J]. Am J Obstet Gynecol, 2008, 198(6): 635.e1-635.e6.
[5] GAREY KW, JIANG ZD, YADAV Y, et al.Peripartum clostridium difficile infection: case series and review of the literature[J]. Am J Obstet Gynecol, 2008, 199(4): 332-333.
[6] American College of Obstetricians and Gynecologists. ACOG practice bulletin No.142: cerclage for the management of cervical insufficiency[J]. Obstet Gynecol, 2014, 123(2): 372-379.
[7] MCDONAL C, GERDING DN, JOHNSON S, et al.Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)[J]. Clin Infect Dis, 2018, 66(7): 987-994.
[8] CHENG JW, LIU WE, MA XJ, et al.Expert consensus on diagnosis and treatment of Clostridium difficile infection in Chinese adults[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2017(z1): 131-138.
[9] KELLY CR, FISCHER M, ALLEGRETTI JR, et al.ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections[J]. Am J Gastroenterol, 2021, 116(6): 1124-1147.
[10] CHIHARA S, SHIMIZU R, FURUKATA S, et al.Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis[J]. Scand J Infect Dis, 2011, 43(2): 149-150.
[11] BERGERON L, BOUCHER FD.Possible red man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function[J]. Ann Pharmacother, 1994, 28(5): 581-584.
[12] BAILEY P, GRAY H.An elderly woman with red man syndrome in association with oral vancomycin therapy: a case report[J]. Cases J, 2008, 1(1): 111.
[13] KILLIAN AD, SAHAI JV, MEMISH ZA.Red man syndrome after oral vancomycin[J]. Ann Intern Med, 1991, 115(5): 410-411.
[14] ARROYO MF, KHUDYAKOV A, CHAWLA GS, et al.Red man syndrome with oral vancomycin: a case report[J]. Am J Med Case Rep, 2019, 7(1): 16-17.
[15] NALLASIVAN M, MAHER F, MURTHY K.Rare case of “red man” syndrome in a female patient treated with oral vancomycin for clostridium difficile diarrhea[J]. BMJ Case Rep, 2009, 2009: bcr03.2009.1705.
[16] LUO JJ, WU XA, XUE G, et al.Red man syndrome caused by oral vancomycin[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2021, 23(4): 221-223.
[17] MCCULLOUGH JM, DIELMAN DG, PEERY D, et al.Oral vancomycin-induced rash: case report and review of the literature[J]. Ann Pharmacother, 1991, 25(12): 1326-1328.
[18] BARRON J, LATTES A, MARCUS EL.Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature[J]. Allergy Asthma Clin Immunol, 2018, 14: 73.
[19] OSAWA R, KAKA AS.Maculopapular rash induced by oral vancomycin[J]. Clin Infect Dis, 2008, 47(6): 860-861.
[20] ZHU YH, HUANG JQ.A case of facial rash caused by Clostridium difficile infection treated with oral vancomycin in children and literature review[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2021(3): 44-46.
[21] GOMCELI U, VANGALA S, ZEANA C, et al.An unusual case of ototoxicity with use of oral vancomycin[J]. Case Rep Infect Dis, 2018, 2018: 2980913.
[22] BAUMGARTNER LJ, BROWN L, GEIER C.Hypersensitivity reaction following administration of low-dose oral vancomycin for the treatment of clostridium difficile in a patient with normal renal function[J]. J Pharm Pract, 2017, 30(6): 650-652.
[23] ALMOHAMMADI A, SHAHADA O, ALMADANI AZ, at el. Uncommon case of oral vancomycin neurotoxicity with sexual dysfunction[J]. Cureus, 2020, 12(12): e12396.
[24] ARADHYULA S, MANIAN FA, HAFIDH SA, et al.Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function[J]. South Med J, 2006, 99(5): 518-520.
[25] ARMSTRONG CJ, WILSON TS.Systemic absorption of vancomycin[J]. J Clin Pathol, 1995, 48(7): 689.
[26] HOLLIER A.Clinical guidelines in primary care//Medication use in pregnancy[M]. 2nd ed. Advanced Practice Education Associates, 2016: 581-584.
[27] BLATTNER CM, DANESH M, SAFAEE M, et al.Understanding the new FDA pregnancy and lactation labeling rules[J]. International Journal of Women’s Dermatology, 2016, 2(1): 5-7.
[28] LU YN, BAI RX, YANG YH.Application status and suggestions of pharmacovigilance in drug therapy during pregnancy[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(3): 279-282.
[29] NWOSU OC, BLOOM K.The safety of metronidazole in pregnancy[J]. Health Care For Women International, 2021, 42(4-6): 726-738.
[30] HUNGIN APS, MITCHELL CR, WHORWELL P, et al.Systematic review:probiotics in the management of lower gastrointestinal symptoms-an updated evidence based international consensus[J]. Aliment Pharmacol Ther,2018, 47(8): 1054-1070.
[31] YIN YS, SUN WY.Diagnosis and treatment of pregnancy complicated with urinary tract infection[J]. Chinese Journal of Nephrology(中华肾病研究电子杂志), 2015(4): 196-199.
[32] ORTEGA GY, CASTRO DD.Antibiotic considerations for urinary tract infections in pregnancy[J]. Curr Bladder Dysfunct Rep, 2014, 9:167-174.
[33] European Association of Urology. Guidelines on Urological Infections2015[EB/OL]. (2016-10-26)[2022-02-10]. https://www.docin.com/p-1149531596.html.
[34] SANTOS F, SHEEHY O, PERREAULT S, et al.Use of anti-infective drugs during pregnancy and the risk of preterm birth[J]. International Journal of Antimicrobial Agents, 2012, 39(2): 177-178.